Background Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which
has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the
development of resistance to antiangiogenic drugs. This randomized, open-label, phase 3
trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with
renal-cell carcinoma that had progressed after VEGFR-targeted therapy. Methods We …

Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of
cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell
carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. Here,
we report the final overall survival results from this study based on an unplanned second
interim analysis. Methods In this open-label, randomised phase 3 trial, we randomly …